Euglycemic diabetic ketoacidosis with persistent diuresis treated with canagliflozin

Internal Medicine

Volumn 56, Issue 2, 2017, Pages 187-190

  Adachi, Junichiro ^a   Inaba, Yuusuke ^a   Maki, Chisato ^a  

^a Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

Author keywords

Euglycemic diabetic ketoacidosis; Sodium glucose cotransporter 2 inhibitors

Indexed keywords

3 HYDROXYBUTYRIC ACID; BICARBONATE; C PEPTIDE; CANAGLIFLOZIN; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; KETONE BODY; POTASSIUM; SODIUM; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ACIDEMIA; ADULT; ALKALOSIS; ARTERIAL GAS; ARTICLE; BLOOD CARBON DIOXIDE TENSION; BLOOD GAS ANALYSIS; BLOOD OXYGEN TENSION; BLOOD PH; CASE REPORT; CONTINUOUS INFUSION; DIABETIC KETOACIDOSIS; DIURESIS; DIZZINESS; ERYTHROCYTE COUNT; FEMALE; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALAISE; METABOLIC ACIDOSIS; NEUTROPHIL COUNT; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOLALITY; THIRST; THROMBOCYTE COUNT; UPPER ABDOMINAL PAIN; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINE VOLUME; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DIFFERENTIAL DIAGNOSIS;

ADULT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; DIAGNOSIS, DIFFERENTIAL; DIURESIS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85010297406     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.56.7501     Document Type: Article

References (15)

1. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100: 2849-2852, 2015.
2. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 38: 412-419, 2015.
3. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32: 1335-1343, 2009.
4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117-2128, 2015.
5. Matthaei S, Catrinoiu D, Celiński A, et al. Randomized, doubleblind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care 38: 2018-2024, 2015.
6. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. [cited 2015 May 15]. Available from http://www.fda.gov/drugs/drugsafety/ucm446845.htm
7. Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycaemic diabetic ketoacidosis. Br Med J 2: 578-580, 1973.
8. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38: 1680-1686, 2015.
9. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38: 1687-1693, 2015.
10. Hine J, Paterson H, Abrol E, Russell-Jones D, Herring R. SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol 3: 503-504, 2015.
11. Burr K, Nguyen AT, Rasouli N. A case report of ketoacidosis associated with canagliflozin (Invokana). Endocrine Society’s Annual Meeting and Expo 2015: poster board SAT-595.
12. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig 6: 587-590, 2015.
13. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT 2 inhibitors. Diabetes Care 38: 1638-1642, 2015.
14. Sugiyama M, Yoshioka S, Mizoguchi A, Shinohara Y, Akahane K, Sato I. A case of type 2 diabetes patient with severe dehydration and diabetic ketoacidosis induced by excess intake of soft drinks due to coexisting central diabetes insipidus. J Japan Diab Soc 58: 835-841, 2015 (in Japanese, Abstract in English).
15. Shin HJ, Kim JH, Yi JH, Han SW, Kim HJ. Polyuria with the concurrent manifestation of central diabetes insipidus (CDI) & Type 2 diabetes mellitus (DM). Electrolyte Blood Press 10: 26-30, 2012.